Your browser doesn't support javascript.
loading
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.
Mammen, Andrew L; Amato, Anthony A; Dimachkie, Mazen M; Chinoy, Hector; Hussain, Yessar; Lilleker, James B; Pinal-Fernandez, Iago; Allenbach, Yves; Boroojerdi, Babak; Vanderkelen, Mark; Delicha, Eumorphia Maria; Koendgen, Harold; Farzaneh-Far, Ramin; Duda, Petra W; Sayegh, Camil; Benveniste, Olivier.
Afiliación
  • Mammen AL; Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Amato AA; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Dimachkie MM; Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas USA.
  • Chinoy H; National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK; Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science
  • Hussain Y; Austin Neuromuscular Center, The University of Texas Dell Medical School, Austin, Texas, USA.
  • Lilleker JB; Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Manchester, UK; Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Cen
  • Pinal-Fernandez I; Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Allenbach Y; Department of Internal Medicine and Clinical Immunology, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France; Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMR
  • Boroojerdi B; UCB Pharma, Monheim, Germany.
  • Vanderkelen M; UCB Pharma, Braine-l'Alleud, Belgium.
  • Delicha EM; UCB Pharma, Braine-l'Alleud, Belgium.
  • Koendgen H; UCB Pharma, Bulle, Switzerland.
  • Farzaneh-Far R; Ra Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Duda PW; UCB Pharma, Cambridge, Massachusetts, USA.
  • Sayegh C; UCB Pharma, Cambridge, Massachusetts, USA.
  • Benveniste O; Department of Internal Medicine and Clinical Immunology, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France; Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMR
Lancet Rheumatol ; 5(2): e67-e76, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36923454
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Lancet Rheumatol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Lancet Rheumatol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos